Hims & Hers Health, Inc. (NYSE:HIMS) Receives $38.25 Average PT from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $38.25.

Several research firms recently issued reports on HIMS. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Leerink Partners boosted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Finally, Piper Sandler raised their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th.

Hims & Hers Health Stock Up 5.4 %

HIMS stock opened at $28.14 on Friday. The business’s 50-day moving average price is $34.85 and its 200-day moving average price is $30.84. The stock has a market cap of $6.25 billion, a P/E ratio of 63.96 and a beta of 1.65. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. On average, equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at approximately $983,271.96. This trade represents a 78.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Irene Becklund sold 2,203 shares of the company’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the transaction, the insider now directly owns 8,007 shares in the company, valued at $230,441.46. This trade represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 712,998 shares of company stock valued at $27,992,450. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC raised its stake in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after buying an additional 628 shares during the period. Cim LLC grew its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after buying an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. increased its stake in shares of Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after buying an additional 833 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.